Israel Englander Mereo Biopharma Group PLC Transaction History

Millennium Management LLC

$192 Billion
Q4 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Millennium Management LLC holds 47,700 shares of MREO stock, worth $139,761. This represents 0.0% of its overall portfolio holdings.

Number of Shares

47,700

Previous 5,394,691 99.12%

Holding current value

$139,761

Previous $22.2 Million 99.25%

% of portfolio

0.0%

Previous 0.01%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$3.29 - $4.62 $4.7 Million - $6.6 Million	-1,429,259 Reduced 26.49%	3,965,432 $13.9 Million
Q3 2024 Nov 14, 2024	BUY	$3.45 - $4.87 $7.57 Million - $10.7 Million	2,192,986 Added 68.49%	5,394,691 $22.2 Million
Q2 2024 Aug 14, 2024	BUY	$2.58 - $4.25 $2.64 Million - $4.35 Million	1,022,570 Added 46.93%	3,201,705 $11.5 Million
Q1 2024 May 15, 2024	BUY	$2.3 - $4.05 $1.77 Million - $3.11 Million	768,818 Added 54.51%	2,179,135 $7.19 Million
Q4 2023 Feb 14, 2024	BUY	$1.19 - $2.42 $541,742 - $1.1 Million	455,246 Added 47.67%	1,410,317 $3.26 Million
Q2 2023 Aug 14, 2023	SELL	$0.79 - $1.43 $1.22 Million - $2.22 Million	-1,550,559 Reduced 61.88%	955,071 $1.26 Million
Q1 2023 May 15, 2023	BUY	$0.71 - $1.22 $847,939 - $1.46 Million	1,194,281 Added 91.07%	2,505,630 $1.77 Million
Q4 2022 Feb 14, 2023	BUY	$0.5 - $1.01 $28,869 - $58,315	57,738 Added 4.61%	1,311,349 $984,000
Q3 2022 Nov 14, 2022	BUY	$0.82 - $1.73 $452,406 - $954,466	551,715 Added 78.6%	1,253,611 $1.08 Million

Others Institutions Holding MREO

# of Institutions

Shares Held

114M

Call Options Held

83.4K

Put Options Held

424K

View Full List

About Mereo Biopharma Group plc

Ticker MREO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,986,000
Market Cap $366M
Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...

More about MREO

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account